Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
| ▸ | TYK2 | P29597 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25813723 | 0.89 | LRRK2 (0.38) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL103509 | 0.84 | JAK2 (0.38) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL103508 | 0.84 | JAK2 (0.38) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL102017 | 0.80 | ALK (0.34) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL102018 | 0.80 | ALK (0.34) | JAK1JAK2JAK3TYK2DGAT1 | |
| SCHEMBL19601282 | 0.80 | SIGMAR1 (0.43) | DGAT1LRRK2 | |
| SCHEMBL12732015 | 0.80 | JAK2 (0.34) | JAK1JAK2JAK3TYK2LRRK2 | |
| SCHEMBL103551 | 0.79 | RET (0.34) | DGAT1LRRK2 | |
| SCHEMBL103550 | 0.79 | RET (0.34) | DGAT1LRRK2 | |
| SCHEMBL1602689 | 0.79 | JAK2 (0.46) | JAK1JAK2JAK3TYK2LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200038404-A1 | METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | INCYTE CORP (US) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038404-A1 | METABOLITES OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE | JAK2, JAK3, JAK1 | JAK1 3/4885JAK2 1/4885JAK3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.